2 September 2020 - - US-based immunotherapies developer HDT Bio Corp. recently received a notice of award from the National Institute of Allergy and Infectious Disease at the National Institutes of Health, the company said.

The approved contract provides USD 8.2m in support of pre-clinical and clinical activities to be conducted by HDT and collaborators to accelerate development of HDT-301 a COVID-19 vaccine candidate.

With a focus on RNA, formulation, and adjuvant technologies, HDT Bio is developing biotherapeutics for oncology and infectious disease applications.

HDT Bio simultaneously works to integrate therapeutic approaches for first-in-class medicines while building on decades of development experience with well-established pharmaceutical ingredients.

The resulting products are poised to significantly improve the lives of millions of people worldwide and to provide access to lifesaving therapies for underserved populations.

One of the company's core technologies, RNA/LION, combines formulation and adjuvant ingredients to stabilise and deliver RNA to the immune system to stimulate responses for therapy or vaccination.